139 related articles for article (PubMed ID: 24885059)
1. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.
Quandt D; Jasinski-Bergner S; Müller U; Schulze B; Seliger B
J Transl Med; 2014 May; 12():151. PubMed ID: 24885059
[TBL] [Abstract][Full Text] [Related]
2. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
Falkensammer C; Jöhrer K; Gander H; Ramoner R; Putz T; Rahm A; Greil R; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2006 Oct; 55(10):1228-37. PubMed ID: 16810557
[TBL] [Abstract][Full Text] [Related]
3. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Thompson RH; Gillett MD; Cheville JC; Lohse CM; Dong H; Webster WS; Krejci KG; Lobo JR; Sengupta S; Chen L; Zincke H; Blute ML; Strome SE; Leibovich BC; Kwon ED
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17174-9. PubMed ID: 15569934
[TBL] [Abstract][Full Text] [Related]
4. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.
Maeurer MJ; Martin DM; Castelli C; Elder E; Leder G; Storkus WJ; Lotze MT
Cancer Immunol Immunother; 1995 Aug; 41(2):111-21. PubMed ID: 7656270
[TBL] [Abstract][Full Text] [Related]
5. Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Umekita S; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Oda Y
J Clin Pathol; 2024 Jan; 77(2):105-110. PubMed ID: 36347592
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of a highly immunogenic human renal carcinoma cell line.
Prattichizzo C; Gigante M; Pontrelli P; Stella A; Rocchetti MT; Gigante M; Maiorano E; Herr W; Battaglia M; Gesualdo L; Ranieri E
Int J Oncol; 2016 Aug; 49(2):457-70. PubMed ID: 27278998
[TBL] [Abstract][Full Text] [Related]
7. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer.
de Cubas AA; Dunker W; Zaninovich A; Hongo RA; Bhatia A; Panda A; Beckermann KE; Bhanot G; Ganesan S; Karijolich J; Rathmell WK
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32493845
[TBL] [Abstract][Full Text] [Related]
8. B7-H3 suppresses CD8
Wu Y; Han W; Tang X; Liu J; Guo Z; Li Z; Cai C; Que L
J Cancer; 2024; 15(9):2505-2517. PubMed ID: 38577598
[TBL] [Abstract][Full Text] [Related]
9. Pathological findings directing immunotherapy in renal cell carcinomas.
Gökalp Satıcı FE; Karabulut YY
Immunotherapy; 2024 Mar; 16(4):199-204. PubMed ID: 38214137
[TBL] [Abstract][Full Text] [Related]
10. Correlations between components of the immune system.
Shabat Y; Ilan Y
F1000Res; 2021; 10():1174. PubMed ID: 38628268
[TBL] [Abstract][Full Text] [Related]
11. Retraction Note to: Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma.
Safaei HR; Rostamzadeh A; Rahmani O; Mohammadi M; Ghaderi O; Yahaghi H; Ahmadi K
Tumour Biol; 2016 Nov; ():. PubMed ID: 27826944
[No Abstract] [Full Text] [Related]
12. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Ritprajak P; Azuma M
Oral Oncol; 2015 Mar; 51(3):221-8. PubMed ID: 25500094
[TBL] [Abstract][Full Text] [Related]
13. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
Leung J; Suh WK
Immune Netw; 2014 Dec; 14(6):265-76. PubMed ID: 25550693
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms Controlling PD-L1 Expression in Cancer.
Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
[TBL] [Abstract][Full Text] [Related]
16. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Chan LC; Li CW; Xia W; Hsu JM; Lee HH; Cha JH; Wang HL; Yang WH; Yen EY; Chang WC; Zha Z; Lim SO; Lai YJ; Liu C; Liu J; Dong Q; Yang Y; Sun L; Wei Y; Nie L; Hsu JL; Li H; Ye Q; Hassan MM; Amin HM; Kaseb AO; Lin X; Wang SC; Hung MC
J Clin Invest; 2019 Jul; 129(8):3324-3338. PubMed ID: 31305264
[TBL] [Abstract][Full Text] [Related]
17. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Cha JH; Yang WH; Xia W; Wei Y; Chan LC; Lim SO; Li CW; Kim T; Chang SS; Lee HH; Hsu JL; Wang HL; Kuo CW; Chang WC; Hadad S; Purdie CA; McCoy AM; Cai S; Tu Y; Litton JK; Mittendorf EA; Moulder SL; Symmans WF; Thompson AM; Piwnica-Worms H; Chen CH; Khoo KH; Hung MC
Mol Cell; 2018 Aug; 71(4):606-620.e7. PubMed ID: 30118680
[TBL] [Abstract][Full Text] [Related]
18. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.
Yang Y; Li CW; Chan LC; Wei Y; Hsu JM; Xia W; Cha JH; Hou J; Hsu JL; Sun L; Hung MC
Cell Res; 2018 Aug; 28(8):862-864. PubMed ID: 29959401
[No Abstract] [Full Text] [Related]
19. Regulation and Function of the PD-L1 Checkpoint.
Sun C; Mezzadra R; Schumacher TN
Immunity; 2018 Mar; 48(3):434-452. PubMed ID: 29562194
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA; de Carné Trécesson S; Rana S; Zecchin D; Moore C; Molina-Arcas M; East P; Spencer-Dene B; Nye E; Barnouin K; Snijders AP; Lai WS; Blackshear PJ; Downward J
Immunity; 2017 Dec; 47(6):1083-1099.e6. PubMed ID: 29246442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
